van de Bovenkamp AA - Search Results

1

Long-term hemodynamic responses and reverse remodeling after pharmacotherapy in HFpEF versus HFrEF: a systematic review and meta-analysis.

van de Bovenkamp AA, Nassiri S, Bakermans AJ, Burchell GL, de Man FS, van Loon RB, Handoko ML. van de Bovenkamp AA, et al. Am J Physiol Heart Circ Physiol. 2025 Jan 18. doi: 10.1152/ajpheart.00544.2024. Online ahead of print. Am J Physiol Heart Circ Physiol. 2025. PMID: 39825764

2

Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis.

Nassiri S, Van de Bovenkamp AA, Remmelzwaal S, Sorea O, de Man F, Handoko ML. Nassiri S, et al. Among authors: van de bovenkamp aa. Open Heart. 2024 May 8;11(1):e002579. doi: 10.1136/openhrt-2023-002579. Open Heart. 2024. PMID: 38719498 Free PMC article.

3

Recurrent angina and cardiac ischaemia as a presentation of pheochromocytoma: a case report.

van de Bovenkamp AA, Kalkman DN, Beijk MAM, van de Veerdonk MC. van de Bovenkamp AA, et al. Eur Heart J Case Rep. 2024 Mar 21;8(4):ytae153. doi: 10.1093/ehjcr/ytae153. eCollection 2024 Apr. Eur Heart J Case Rep. 2024. PMID: 38645675 Free PMC article.

4

Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.

van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, de Man FS, Kok WEM, Bronzwaer PNA, Allaart CP, Nederveen AJ, van Rossum AC, Bakermans AJ, Handoko ML. van de Bovenkamp AA, et al. ESC Heart Fail. 2023 Oct;10(5):2998-3010. doi: 10.1002/ehf2.14418. Epub 2023 Aug 2. ESC Heart Fail. 2023. PMID: 37530098 Free PMC article. Clinical Trial.

5

The Dynamic Relationship Between Invasive Microvascular Function and Microvascular Injury Indicators, and Their Association With Left Ventricular Function and Infarct Size at 1-Month After Reperfused ST-Segment-Elevation Myocardial Infarction.

Demirkiran A, Robbers LFHJ, van der Hoeven NW, Everaars H, Hopman LHGA, Janssens GN, Berkhof HJ, Lemkes JS, van de Bovenkamp AA, van Leeuwen MAH, Nap A, van Loon RB, de Waard GA, van Rossum AC, van Royen N, Nijveldt R. Demirkiran A, et al. Among authors: van de bovenkamp aa. Circ Cardiovasc Interv. 2022 Nov;15(11):892-902. doi: 10.1161/CIRCINTERVENTIONS.122.012081. Epub 2022 Oct 28. Circ Cardiovasc Interv. 2022. PMID: 36305318

6

Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea.

Reddy YNV, Kaye DM, Handoko ML, van de Bovenkamp AA, Tedford RJ, Keck C, Andersen MJ, Sharma K, Trivedi RK, Carter RE, Obokata M, Verbrugge FH, Redfield MM, Borlaug BA. Reddy YNV, et al. Among authors: van de bovenkamp aa. JAMA Cardiol. 2022 Sep 1;7(9):891-899. doi: 10.1001/jamacardio.2022.1916. JAMA Cardiol. 2022. PMID: 35830183 Free PMC article.

7

The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction.

van de Bovenkamp AA, Wijkstra N, Oosterveer FPT, Vonk Noordegraaf A, Bogaard HJ, van Rossum AC, de Man FS, Borlaug BA, Handoko ML. van de Bovenkamp AA, et al. Circ Heart Fail. 2022 Apr;15(4):e008935. doi: 10.1161/CIRCHEARTFAILURE.121.008935. Epub 2022 Mar 21. Circ Heart Fail. 2022. PMID: 35311526 Free PMC article.

8

Validation of the 2016 ASE/EACVI Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction.

van de Bovenkamp AA, Enait V, de Man FS, Oosterveer FTP, Bogaard HJ, Vonk Noordegraaf A, van Rossum AC, Handoko ML. van de Bovenkamp AA, et al. J Am Heart Assoc. 2021 Sep 21;10(18):e021165. doi: 10.1161/JAHA.121.021165. Epub 2021 Sep 3. J Am Heart Assoc. 2021. PMID: 34476984 Free PMC article.

9

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

van de Bovenkamp AA, van Rossum AC, Handoko ML. van de Bovenkamp AA, et al. N Engl J Med. 2020 Mar 19;382(12):1180. doi: 10.1056/NEJMc2000284. N Engl J Med. 2020. PMID: 32187476 No abstract available.

10

TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study.

van de Bovenkamp AA, Bakermans AJ, Allaart CP, Nederveen AJ, Kok WEM, van Rossum AC, Handoko ML. van de Bovenkamp AA, et al. Neth Heart J. 2020 Jun;28(6):312-319. doi: 10.1007/s12471-020-01407-z. Neth Heart J. 2020. PMID: 32162204 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters